A Phase.b Study of D-0502 as Monotherapy for Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer: Results from the Dose-Expansion Stage

被引：0
|
作者：
Wang, Jiayu
Sun, Tao
Zhang, Qingyuan
Shi, Yanxia
Wang, Xu
Chen, Yiding
Ouyang, Quchang
Li, Kunyan
Bupathi, Manojkumar
Edenfield, W. Jeffery
Silber, Andrea L. M.
Zong, Hong
Hamilton, Erika
Juric, Dejan
Lathrop, Kate
Zhang, Yihong
Stazzone, Kathryn
Shi, Zhe
Wang, Yaolin
Zhang, Ling
Xu, Binghe
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PS15-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS15-02
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A phase 1 study of D-0502, an orally bioavailable SERD, for advanced or metastatic HR-positive and HER2-negative breast cancer
    Osborne, Cynthia
    Richards, Donald A.
    Wilks, Sharon T.
    Diab, Sami
    Juric, Dejan
    Lathrop, Kate
    Silber, Andrea
    Edenfield, William
    Aulakh, Amardeep
    Cho, Ben
    Xu, Binghe
    Sun, Tao
    Ouyang, Quchang
    Shi, Yanxia
    Stazzone, Kathryn
    Shi, Zhe
    Zhang, Ling
    Wang, Yaolin
    Hamilton, Erika P.
    CANCER RESEARCH, 2021, 81 (04)
  • [2] Elacestrant for ER-Positive HER2-Negative Advanced Breast Cancer
    Hageman, Elizabeth
    Lussier, Mia E.
    ANNALS OF PHARMACOTHERAPY, 2024, 58 (08) : 849 - 856
  • [3] Elacestrant in advanced ER-positive, HER2-negative breast cancer
    Kuenzell, Judith Lorenz
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (01) : 16 - 16
  • [4] Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer
    Reinert, Tomas
    de Paula, Bruno
    Shafaee, Maryam Nemati
    Souza, Pedro Henrique
    Ellis, Matthew J.
    Bines, Jose
    CHINESE CLINICAL ONCOLOGY, 2018, 7 (03)
  • [5] Challenges in the management of advanced, ER-positive, HER2-negative breast cancer
    Christopher D. Hart
    Ilenia Migliaccio
    Luca Malorni
    Cristina Guarducci
    Laura Biganzoli
    Angelo Di Leo
    Nature Reviews Clinical Oncology, 2015, 12 : 541 - 552
  • [6] Palbociclib and letrozole for ER-positive, HER2-negative advanced breast cancer
    Abraham, Jame
    Mechcatie, Elizabeth
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2015, 13 (03): : 83 - 86
  • [7] Challenges in the management of advanced, ER-positive, HER2-negative breast cancer
    Hart, Christopher D.
    Migliaccio, Ilenia
    Malorni, Luca
    Guarducci, Cristina
    Biganzoli, Laura
    Di Leo, Angelo
    NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (09) : 541 - 552
  • [8] Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer
    Hoste, G.
    Punie, K.
    Wildiers, H.
    Beuselinck, B.
    Lefever, I.
    Van Nieuwenhuysen, E.
    Han, S. N.
    Berteloot, P.
    Concin, N.
    Salihi, R.
    Vergote, I.
    Neven, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 171 (01) : 131 - 141
  • [9] Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer
    G. Hoste
    K. Punie
    H. Wildiers
    B. Beuselinck
    I. Lefever
    E. Van Nieuwenhuysen
    S. N. Han
    P. Berteloot
    N. Concin
    R. Salihi
    I. Vergote
    P. Neven
    Breast Cancer Research and Treatment, 2018, 171 : 131 - 141
  • [10] A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results
    Hamilton, E.
    Oliveira, M.
    Turner, N.
    Garcia-Corbacho, J.
    Hernando, C.
    Ciruelos, E. M.
    Kabos, P.
    Ruiz-Borrego, M.
    Armstrong, A.
    Patel, M. R.
    Vaklavas, C.
    Twelves, C.
    Boni, V.
    Incorvati, J.
    Brier, T.
    Gibbons, L.
    Klinowska, T.
    Lindemann, J. P. O.
    Morrow, C. J.
    Sykes, A.
    Baird, R. D.
    ANNALS OF ONCOLOGY, 2024, 35 (08) : 707 - 717
12345